Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenABCWY booster extension study after V102_03
2012-003937-41Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2013
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Meningococcal ABCWY in meningococcal disease (3 arms), sponsored by GSK. Primary endpoints: Seroresponse for meningococcal serogroups A, C, W and Y at Day 30, hSBA response for serogroup B strains at Day 30 and 1 more. Started Dec 2013; status: completed.
02
Drugs
Meningococcal ABCWY
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2012-003937-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003937-41.